Therapeutic approaches for the treatment of Friedreich’s ataxia

References

• Lynch DR, Farmer JM, Balcer LJ, Wilson RB. Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol 2002;59(5):743-7
   PubMed Web of Science ®Google Scholar
• Dürr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med 1996;335(16):169-1175
   Web of Science ®Google Scholar
• Harding AE. Friedreich’s ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981;104(3):589-620
   PubMed Web of Science ®Google Scholar
• Tsou AY, Paulsen EK, Lagedrost SJ, et al. Mortality in Friedreich ataxia. J Neurol Sci 2011;307(1-2):46-9
   PubMed Web of Science ®Google Scholar
• Nachbauer W, Bodner T, Boesch S, et al. Friedreich ataxia: executive control is related to disease onset and GAA repeat length. Cerebellum 2014;13(1):9-16
   PubMed Web of Science ®Google Scholar
• Parkinson MH, Boesch S, Nachbauer W, et al. Clinical features of Friedreich’s ataxia: classical and atypical phenotypes. J Neurochem 2013;126(Suppl 1):103-17
   PubMed Web of Science ®Google Scholar
• Campuzano V, Montermini L, Moltò MD, et al. Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271(5254):1423-7
   PubMed Web of Science ®Google Scholar
• Pandolfo M. Molecular pathogenesis of Friedreich ataxia. Arch Neurol 1999;56(10):1201-8
   PubMedGoogle Scholar
• Metz G, Coppard N, Cooper JM, et al. Rating disease progression of Friedreich’s ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database. Brain 2013;136(Pt 1):259-68
   PubMed Web of Science ®Google Scholar
• González-Cabo P, Palau F. Mitochondrial pathophysiology in Friedreich’s ataxia. J Neurochem 2013;126(Suppl 1):53-64
   PubMed Web of Science ®Google Scholar
• Suno M, Nakaoka A. Inhibition of lipid peroxidation by a novel compound, idebenone (CV-2619). Jap J Pharmacol 1984;35(2):196-8
   PubMedGoogle Scholar
• Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, et al. Effect of idebenone on cardiomyopathy in Friedreich’s ataxia: a preliminary study. Lancet 1999;354(9177):477-9
   PubMed Web of Science ®Google Scholar
• Hausse AO, Aggoun Y, Bonnet D, et al. Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia. Heart 2002;87(4):346-9
   PubMed Web of Science ®Google Scholar
• Mariotti C, Solari A, Torta D, et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003;60(10):1676-9
   PubMed Web of Science ®Google Scholar
• Buyse G, Mertens L, Di Salvo G, et al. Idebenone treatment in Friedreich’s ataxia: neurological, cardiac, and biochemical monitoring. Neurology 2003;60(10):1679-81
   PubMed Web of Science ®Google Scholar
• Lagedrost SJ, Sutton MS, Cohen MS, et al. Idebenone in Friedreich ataxia cardiomyopathy—results from a 6-month phase III study (IONIA). Am Heart J 2011;161(3):639-45
   PubMed Web of Science ®Google Scholar
• Artuch R, Aracil A, Mas A, et al. Friedreich’s ataxia: idebenone treatment in early stage patients. Neuropediatrics 2002;33(4):190-3
   PubMed Web of Science ®Google Scholar
• Pineda M, Arpa J, Montero R, et al. Idebenone treatment in paedeatric and adult patients with Friedreich’s ataxia: long-term follow-up. Eur J Paediatr Neurol 2008;12(6):470-5
   PubMed Web of Science ®Google Scholar
• Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2007;6(10):878-86
   PubMed Web of Science ®Google Scholar
• Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch Neurol 2010;67(8):941-7
   PubMed Web of Science ®Google Scholar
• Meier T, Perlman SL, Rummey C, et al. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich’s ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol 2012;259(2):284-91
   PubMed Web of Science ®Google Scholar
• Myers L, Farmer JM, Wilson RB, et al. Antioxidant use in Friedreich ataxia. J Neurol Sci 2008;267(1-2):174-6
   PubMed Web of Science ®Google Scholar
• Arpa J, Sanz-Gallego I, Rodríguez-de-Rivera FJ, et al. Triple therapy with darbepoetin alfa, idebenone, and riboflavin in Friedreich’s ataxia: an open-label trial. Cerebellum 2013;12(5):713-20
   PubMed Web of Science ®Google Scholar
• Parkinson MH, Schulz JB, Giunti P. Co-enzyme Q10 and idebenone use in Friedreich’s ataxia. J Neurochem 2013;126(Suppl 1):125-41
   PubMed Web of Science ®Google Scholar
• Lodi R, Hart PE, Rajagopalan B, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. Ann Neurol 2001;49(5):590-6
   PubMed Web of Science ®Google Scholar
• Cooper JM, Schapira AH. Friedreich’s ataxia: disease mechanisms, antioxidant and coenzyme Q10 therapy. Biofactors 2003;18(1-4):163-71
   PubMed Web of Science ®Google Scholar
• Hart PE, Lodi R, Rajagopalan B, et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 2005;62(4):621-6
   PubMedGoogle Scholar
• Cooper JM, Korlipara LV, Hart PE, et al. Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol 2008;15(12):1371-9
   PubMed Web of Science ®Google Scholar
• Martinelli D, Catteruccia M, Piemonte F, et al. EPI-743 reverses the progression of the pediatric mitochondrial diseases – genetically defined Leigh syndrome. Mol Genet Metab 2012;107(3):383-8
   PubMed Web of Science ®Google Scholar
• Sadun AA, Chicani CF, Ross-Cisneros FN, et al. Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy. Arch Neurol 2012;69(3):331-8
   PubMed Web of Science ®Google Scholar
• Enns GM, Kinsman SL, Perlman SL, et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab 2012;105(1):91-102
   PubMed Web of Science ®Google Scholar
• FARA research pipeline. Available from: www.curefa.org/pipeline.html
   Google Scholar
• FDA Grants Edison pharmaceuticals’ EPI-743 orphan status for Friedreich’s ataxia – EPI-743 in Phase II development for Friedreich’s ataxia. Available from: www.prnewswire.com/news-releases/fda-grants-edison-pharmaceuticals-epi-743-orphan-status-for-friedreichs-ataxia-243439351.html
   Google Scholar
• FDA awards fast track status to Edison pharmaceuticals’ EPI-743 for Friedreich’s ataxia-EPI-743 in two phase 2 development studies for Friedreich’s ataxia. Available from: www.prnewswire.com/news-releases/fda-awards-fast-track-status-to-edison-pharmaceuticals-epi-743-for-friedreichs-ataxia-250558901.html
   Google Scholar
• Bendheim PE, Poeggeler B, Neria E, et al. Development of indole-3-propionic acid (OXIGON) for Alzheimer’s disease. J Mol Neurosci 2002;19(1-2):213-17
   PubMed Web of Science ®Google Scholar
• Hwang IK, Yoo KY, Li H, et al. Indole-3-propionic acid attenuates neuronal damage and oxidative stress in the ischemic hippocampus. J Neurosci Res 2009;87(9):2126-37
   PubMed Web of Science ®Google Scholar
• Chyan YJ, Poeggeler B, Omar RA, et al. Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J Biol Chem 1999;274(31):21937-42
   PubMed Web of Science ®Google Scholar
• ViroPharma licenses rights from intellect neurosciences for product candidate for Friedreich’s ataxia. Available from: www.prnewswire.com/news-releases/viropharma-licenses-rights-from-intellect-neurosciences-for-product-candidate-for-friedreichs-ataxia-130841723.html
   Google Scholar
• Pandolfo M, Hausmann L. Deferiprone for the treatment of Friedreich’s ataxia. J Neurochem 2013;126(Suppl 1):142-6
   PubMed Web of Science ®Google Scholar
• Boddaert N, Le Quan Sang KH, Rötig A, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007;110(1):401-8
   PubMed Web of Science ®Google Scholar
• Velasco-Sánchez D, Aracil A, Montero R, et al. Combined therapy with idebenone and deferiprone in patients with Friedreich’s ataxia. Cerebellum 2011;10(1):1-8
   PubMed Web of Science ®Google Scholar
• Coppola G, Marmolino D, Lu D, et al. Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich’s ataxia. Hum Mol Genet 2009;18(13):2452-61
   PubMed Web of Science ®Google Scholar
• Marmolino D, Manto M, Acquaviva F, et al. PGC-1alpha down-regulation affects the antioxidant response in Friedreich’s ataxia. PLoS One 2010;5(4):e10025
   PubMed Web of Science ®Google Scholar
• Shin JH, Ko HS, Kang H, et al. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson’s disease. Cell 2011;144(5):689-702
   PubMed Web of Science ®Google Scholar
• Cotticelli MG, Crabbe AM, Wilson RB, Shchepinov MS. Insights into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids. Redox Biol 2013;1:398-404
   PubMed Web of Science ®Google Scholar
• Shchepinov MS, Chou VP, Pollock E, et al. Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson’s disease. Toxicol Lett 2011;207(2):97-103
   PubMed Web of Science ®Google Scholar
• Lynch DR, Deutsch EC, Wilson RB, Tennekoon G. Unanswered questions in Friedreich ataxia. J Child Neurol 2012;27(9):1223-9
   PubMed Web of Science ®Google Scholar
• Bayot A, Santos R, Camadro JM, Rustin P. Friedreich’s ataxia: the vicious circle hypothesis revisited. BMC Med 2011;9:112
   PubMedGoogle Scholar
• Sturm B, Stupphann D, Kaun C, et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Invest 2005;35(11):711-17
   PubMed Web of Science ®Google Scholar
• Boesch S, Sturm B, Hering S, et al. Neurological effects of recombinant human erythropoietin in Friedreich’s ataxia: a clinical pilot trial. Mov Disord 2008;23(13):1940-4
   PubMed Web of Science ®Google Scholar
• Saccà F, Piro R, De Michele G, et al. Epoetin alfa increases frataxin production in Friedreich’s ataxia without affecting hematocrit. Mov Disord 2011;26(4):739-42
   PubMed Web of Science ®Google Scholar
• Nachbauer W, Hering S, Seifert M, et al. Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia – a dose-response trial. Cerebellum 2011;10(4):763-9
   PubMed Web of Science ®Google Scholar
• Mariotti C, Fancellu R, Caldarazzo S, et al. Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov Disord 2012;27(3):446-9
   PubMed Web of Science ®Google Scholar
• Boesch S, Nachbauer W, Mariotti C, et al. Safety and tolerability of carbamylated erythropoietin in Friedreich’s ataxia. Mov Disord 2014; In press
   PubMedGoogle Scholar
• Vyas PM, Tomamichel WJ, Pride PM, et al. A TAT–Frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich’s ataxia mouse model. Hum Mol Genet 2012;21(6):1230-47
   PubMed Web of Science ®Google Scholar
• Tomassini B, Arcuri G, Fortuni S, et al. Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model. Hum Mol Genet 2012;21(13):2855-61
   PubMed Web of Science ®Google Scholar
• Interferon gamma-1b in FRDA. Available from: https://clinicaltrials.gov/ct2/show/NCT01965327?term=interferon+gamma&rank=3
   Google Scholar
• Rai M, Soragni E, Jenssen K, et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One 2008;3(4):e1958
   PubMed Web of Science ®Google Scholar
• Soragni E, Xu C, Plasterer HL, et al. Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia. J Child Neurol 2012;27(9):1164-73
   PubMed Web of Science ®Google Scholar
• Jenssen K, Burnett R, Soragni E, et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich’s ataxia. Nat Chem Biol 2006;2(10):551-8
   PubMedGoogle Scholar
• Chan PK, Torres R, Yandim C, et al. Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich’s ataxia can be reduced upon HDAC inhibition by vitamin B3. Hum Mol Genet 2013;22(13):2662-75
   PubMed Web of Science ®Google Scholar
• Libri V, Yandim C, Athanasopoulos S, et al. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich’s ataxia: an exploratory, open-label, dose-escalation study. Lancet 2014; In press
   PubMedGoogle Scholar
• Perdomini M, Belbellaa B, Monassier L, et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich’s ataxia. Nat Med 2014;20(5):542-7
   PubMed Web of Science ®Google Scholar
• Evans-Galea MV, Pebay A, Dottori M, et al. Cell and gene therapy for Friedreich ataxia- progress to date. Hum Gene Ther 2014; In press
   PubMedGoogle Scholar
• Gomez-Sebastian S, Gimenez-Cassina A, Diaz-Nido J, et al. Infectious delivery and expression of a 135 kb human FRDA genomic DNA locus complements Friedreich’s ataxia deficiency in human cells. Mol Ther 2007;15(2):248-54
   PubMed Web of Science ®Google Scholar
• Pérez-Luz S, Díaz-Nido J. Prospects for the use of artificial chromosomes and minichromosome-like episomes in gene therapy. J Biomed Biotechnol 2010;2010(pii):642804
   PubMedGoogle Scholar
• Gimenez-Cassina A, Wade-Martins R, Gomez-Sebastian S, et al. Infectious delivery and long-term persistence of transgene expression in the brain by a 135-kb iBAC-FXN genomic DNA expression vector. Gene Ther 2011;18(10):1015-19
   PubMed Web of Science ®Google Scholar
• Lim F, Palomo GM, Mauritz C, et al. Functional recovery in a Friedreich’s ataxia mouse model by frataxin gene transfer using an HSV-1 amplicon vector. Mol Ther 2007;15(6):1072-8
   PubMed Web of Science ®Google Scholar